Page last updated: 2024-10-15

3-hydroxykynurenine and Cognitive Decline

3-hydroxykynurenine has been researched along with Cognitive Decline in 2 studies

3-hydroxykynurenine: RN given refers to cpd without isomeric designation
3-hydroxykynurenine : A hydroxykynurenine that is kynurenine substituted by a hydroxy group at position 3.
hydroxykynurenine : A hydroxy-amino acid that is kynurenine substituted by a single hydroxy group at unspecified position. A "closed" class.

Research Excerpts

ExcerptRelevanceReference
" In individuals with prediabetes, 3-hydroxykynurenine (OR per SD 0."8.02Associations between plasma kynurenines and cognitive function in individuals with normal glucose metabolism, prediabetes and type 2 diabetes: the Maastricht Study. ( Bakker, L; Dagnelie, PC; Eussen, SJPM; Köhler, S; Midttun, Ø; Ramakers, IHGB; Schram, MT; Stehouwer, CDA; Ueland, PM; van Boxtel, MPJ; van der Kallen, CJH; van Greevenbroek, MMJ; Verhey, FRJ; Wesselius, A, 2021)
"Several kynurenines were cross-sectionally associated with lower odds of cognitive impairment and better cognitive functioning in type 2 diabetes, while less widespread associations were seen in prediabetes."8.02Associations between plasma kynurenines and cognitive function in individuals with normal glucose metabolism, prediabetes and type 2 diabetes: the Maastricht Study. ( Bakker, L; Dagnelie, PC; Eussen, SJPM; Köhler, S; Midttun, Ø; Ramakers, IHGB; Schram, MT; Stehouwer, CDA; Ueland, PM; van Boxtel, MPJ; van der Kallen, CJH; van Greevenbroek, MMJ; Verhey, FRJ; Wesselius, A, 2021)
"Several studies suggest a pathophysiologically relevant association between increased brain levels of the neuroinhibitory tryptophan metabolite kynurenic acid and cognitive dysfunctions in people with schizophrenia."7.88Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for the pathophysiology of schizophrenia. ( Beggiato, S; Giorgini, F; Notarangelo, FM; Sathyasaikumar, KV; Schwarcz, R, 2018)
"In individuals with type 2 diabetes, kynurenine (0."5.62Associations between plasma kynurenines and cognitive function in individuals with normal glucose metabolism, prediabetes and type 2 diabetes: the Maastricht Study. ( Bakker, L; Dagnelie, PC; Eussen, SJPM; Köhler, S; Midttun, Ø; Ramakers, IHGB; Schram, MT; Stehouwer, CDA; Ueland, PM; van Boxtel, MPJ; van der Kallen, CJH; van Greevenbroek, MMJ; Verhey, FRJ; Wesselius, A, 2021)
" In individuals with prediabetes, 3-hydroxykynurenine (OR per SD 0."4.02Associations between plasma kynurenines and cognitive function in individuals with normal glucose metabolism, prediabetes and type 2 diabetes: the Maastricht Study. ( Bakker, L; Dagnelie, PC; Eussen, SJPM; Köhler, S; Midttun, Ø; Ramakers, IHGB; Schram, MT; Stehouwer, CDA; Ueland, PM; van Boxtel, MPJ; van der Kallen, CJH; van Greevenbroek, MMJ; Verhey, FRJ; Wesselius, A, 2021)
"Several kynurenines were cross-sectionally associated with lower odds of cognitive impairment and better cognitive functioning in type 2 diabetes, while less widespread associations were seen in prediabetes."4.02Associations between plasma kynurenines and cognitive function in individuals with normal glucose metabolism, prediabetes and type 2 diabetes: the Maastricht Study. ( Bakker, L; Dagnelie, PC; Eussen, SJPM; Köhler, S; Midttun, Ø; Ramakers, IHGB; Schram, MT; Stehouwer, CDA; Ueland, PM; van Boxtel, MPJ; van der Kallen, CJH; van Greevenbroek, MMJ; Verhey, FRJ; Wesselius, A, 2021)
"Several studies suggest a pathophysiologically relevant association between increased brain levels of the neuroinhibitory tryptophan metabolite kynurenic acid and cognitive dysfunctions in people with schizophrenia."3.88Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for the pathophysiology of schizophrenia. ( Beggiato, S; Giorgini, F; Notarangelo, FM; Sathyasaikumar, KV; Schwarcz, R, 2018)
"In individuals with type 2 diabetes, kynurenine (0."1.62Associations between plasma kynurenines and cognitive function in individuals with normal glucose metabolism, prediabetes and type 2 diabetes: the Maastricht Study. ( Bakker, L; Dagnelie, PC; Eussen, SJPM; Köhler, S; Midttun, Ø; Ramakers, IHGB; Schram, MT; Stehouwer, CDA; Ueland, PM; van Boxtel, MPJ; van der Kallen, CJH; van Greevenbroek, MMJ; Verhey, FRJ; Wesselius, A, 2021)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Bakker, L1
Ramakers, IHGB1
van Boxtel, MPJ1
Schram, MT1
Stehouwer, CDA1
van der Kallen, CJH1
Dagnelie, PC1
van Greevenbroek, MMJ1
Wesselius, A1
Midttun, Ø1
Ueland, PM1
Verhey, FRJ1
Eussen, SJPM1
Köhler, S1
Beggiato, S1
Notarangelo, FM1
Sathyasaikumar, KV1
Giorgini, F1
Schwarcz, R1

Other Studies

2 other studies available for 3-hydroxykynurenine and Cognitive Decline

ArticleYear
Associations between plasma kynurenines and cognitive function in individuals with normal glucose metabolism, prediabetes and type 2 diabetes: the Maastricht Study.
    Diabetologia, 2021, Volume: 64, Issue:11

    Topics: 3-Hydroxyanthranilic Acid; Aged; Biomarkers; Blood Glucose; Cognition; Cognitive Dysfunction; Cross-

2021
Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for the pathophysiology of schizophrenia.
    Journal of psychopharmacology (Oxford, England), 2018, Volume: 32, Issue:11

    Topics: Animals; Brain; Cognitive Dysfunction; Female; Genotype; Kynurenic Acid; Kynurenine; Kynurenine 3-Mo

2018